首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Permanent epicardial pacing in pediatric patients: seventeen years of experience and 1200 outpatient visits.
【24h】

Permanent epicardial pacing in pediatric patients: seventeen years of experience and 1200 outpatient visits.

机译:小儿患者的永久性心外膜起搏:17年的经验和1200次门诊就诊。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The purpose of this study was to evaluate the long-term outcome of all pediatric epicardial pacing leads. METHODS AND RESULTS: All epicardial leads and 1239 outpatient visits between January 1, 1983, and June 30, 2000, were retrospectively reviewed. Pacing and sensing thresholds were reviewed at implant, at 1 month, and at subsequent 6-month intervals. Lead failure was defined as the need for replacement or abandonment due to pacing or sensing problems, lead fracture, or phrenic/muscle stimulation. A total of 123 patients underwent 207 epicardial lead (60 atrial/147 ventricular, 40% steroid) implantations (median age at implant was 4.1 years [range 1 day to 21 years]). Congenital heart disease was present in 103 (84%) of the patients. Epicardial leads were followed for 29 months (range 1 to 207 months). The 1-, 2-, and 5-year lead survival was 96%, 90%, and 74%, respectively. Compared with conventional epicardial leads, both atrial and ventricular steroid leads had better stimulation thresholds 1 month after implantation; however, only ventricular steroid leads had improved chronic pacing thresholds (at 2 years: for steroid leads, 1.9 muJ [from 0.26 to 16 mu]; for nonsteroid leads, 4.7 muJ [from 0.6 to 25 muJ]; P<0.01). Ventricular sensing was significantly better in steroid leads 1 month after lead implantation (at 2 years: for steroid leads, 8 mV [from 4 to 31 mV]; for nonsteroid leads, 4 mV [from 0.7 to 10 mV]; P<0.01). Neither congenital heart disease, lead implantation with a concomitant cardiac operation, age or weight at implantation, nor the chamber paced was predictive of lead failure. CONCLUSIONS: Steroid epicardial leads demonstrated relatively stable acute and chronic pacing and sensing thresholds. In this evaluation of >200 epicardial leads, lead survival was good, with steroid-eluting leads demonstrating results similar to those found with historical conventional endocardial leads.
机译:背景:这项研究的目的是评估所有小儿心外膜起搏导线的长期结果。方法与结果:回顾性分析了1983年1月1日至2000年6月30日之间的所有心外膜导联和1239例门诊病人。在植入时,1个月和随后的6个月间隔检查起搏和感觉阈值。铅失效的定义是由于起搏或感觉问题,铅断裂或/肌肉刺激而需要更换或放弃。总共123例患者接受了207例心外膜铅植入(60房/ 147心室,类固醇40%)植入(植入时的中位年龄为4.1岁[范围1天至21岁])。 103名(84%)患者患有先天性心脏病。心外膜导联随访29个月(1到207个月)。 1年,2年和5年的铅生存率分别为96%,90%和74%。与常规心外膜导联相比,心房和心室类固醇导联植入后1个月的刺激阈值均更好;然而,只有心室类固醇铅可改善慢性起搏阈值(在2年时:类固醇铅为1.9μJ(从0.26到16μJ);非类固醇铅为4.7μJ(从0.6到25μJ); P <0.01)。植入铅后1个月,类固醇导线的心室感觉明显更好(2年:类固醇导线为8 mV [从4到31 mV];非类固醇导线为4 mV [从0.7到10 mV]; P <0.01) 。先天性心脏病,伴有心脏手术的铅植入术,植入时的年龄或体重,以及房室起搏都不能预示铅衰竭。结论:类固醇心外膜导线显示相对稳定的急性和慢性起搏和感觉阈值。在对> 200个心外膜导联进行的评估中,导联的存活率很好,类固醇洗脱的导联显示的结果与历史上传统的心内膜导联所发现的结果相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号